Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blinded, placebo-controlled trial of acipimox in mitochondrial myopathy
2018-002721-29Phase 3Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of betahistine in Mitochondrial myopathies (MM) (2 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Change in skeletal muscle ATP content. Status: unknown.
02
Drugs
betahistine
03
Conditions
Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on 2018-002721-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002721-29.